Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation-Reference-Cited by-同舟云学术

Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation

Published:2016-10-01 Issue:5 Volume:64 Page:1711-1724
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Paranjpe Shirish¹,Bowen William C.¹,Mars Wendy M.¹,Orr Anne¹,Haynes Meagan M.¹,DeFrances Marie C.¹,Liu Silvia²,Tseng George C.²,Tsagianni Anastasia¹,Michalopoulos George K.¹

Affiliation:

1. Department of Pathology, School of Medicine; University of Pittsburgh; Pittsburgh PA

2. Department of Biostatistics, Graduate School of Public Health; University of Pittsburgh; Pittsburgh PA

Funder

National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases

Cleveland Foundation

Menten Endowment Foundation

Publisher

Wiley

Subject

Hepatology

Reference50 articles.

1. Principles of liver regeneration and growth homeostasis;Michalopoulos;Compr Physiol,2013

2. Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy;Sakamoto;Hepatology,1999

3. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration;Huang;Science,2006

4. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor [comment];Yamada;Hepatology,1998

5. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration;Tan;Gastroenterology,2006

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets;Biochemical Pharmacology;2024-09

2. Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice;Nature Communications;2024-06-12

3. Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations;Lung Cancer;2024-04

4. Molecular Pathways Governing the Termination of Liver Regeneration;Pharmacological Reviews;2024-03-04

5. Basal MET phosphorylation is an indicator of hepatocyte dysregulation in liver disease;Molecular Systems Biology;2024-01-12